The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the
New Combination of Immunotherapy Drugs is Safe, Shrinks Tumors in Metastatic Melanoma Patients, Penn Study Finds
Once again, researchers at Penn’s Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.
Penn Medicine: Investigational Personalized Cellular Therapy Tolerated Well by Patients with Advanced Mesothelioma, Ovarian and Pancreatic Cancers
Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Per
RNA is both the bridge between DNA and the production of proteins that carry out the functions of life and what guides which and how much protein gets made.
Understanding the molecular signals that guide early cells in the embryo to develop into different types of organs provides insight into how tissues regenerate and repair themselves.
Adolescence is a time of frequent and intense emotional experiences, but some youth handle their emotions better than others. Why do some young people react adaptively while others ruminate?
By Madeleine Stone @themadstone
(This is the second in a series of features introducing the inaugural Penn President’s Engagement Prize winners.)
By Julie McWilliams
Emergency department patients have misperceptions about opioid dependence and want more information about their pain management options, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.